BofA analyst Tim Anderson raised the firm’s price target on Bristol Myers (BMY) to $56 from $54 and keeps a Neutral rating on the shares. Q1 beat expectations and guidance was raised, yet the stock was flat as the Q1 report was “fine overall,” but there was “not much new news,” the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target lowered to $53 from $62 at Wells Fargo
- Bristol-Myers Squibb: Hold Rating Amidst Strong Q1 Performance and Long-Term Growth Challenges
- Bristol Myers Squibb Q1 2025 Financial Results Overview
- Bristol-Myers Squibb’s Earnings Call: Strong Growth Amid Challenges
- Unusually active option classes on open April 24th